• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Visualization firms invest in TeraRecon

Article

Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal

Fujifilm and Pentax have invested millions of dollars in TeraRecon as part of strategic alliance agreements that call for the image processing pioneer to collaborate on new product and technology development. Fujifilm of Tokyo, Japan, finalized its deal in March; Pentax signed its agreement in May. Both agreements were announced earlier this month. Fujifilm paid $4.95 million to acquire 300,000 shares of newly issued series G preferred stock, representing a 1.92% equity stake in TeraRecon. Under the terms of the alliance, TeraRecon will apply its signal and image processing technologies to new product and technology development at Fuji. Pentax paid $5.67 million to acquire 341,000 shares of newly issued series G preferred stock, representing 2.18% of issued equity. In return, Pentax has the right to include TeraRecon technology in products such as those involving optical endoscopic imaging and consumer electronics digital camera applications.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.